^
    7ms
    A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov)
    P2, N=125, Recruiting, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HR positive
    |
    capecitabine • Halaven (eribulin mesylate) • TSL1502
    over2years
    A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov)
    P2, N=125, Not yet recruiting, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA (Breast cancer early onset)
    |
    HR positive
    |
    capecitabine • Halaven (eribulin mesylate) • TSL1502